Gamma amino butyric acid receptors (GABA) are major therapeutic targets for the development of drugs in neurological and psychiatric disorders. The new generation of GABA A modulators is targeting subtype selectivity and low/partial efficacy on the receptor to potentially overcome the adverse effects described for drugs with full agonist profile. We evaluated a screening approach to measure the relative efficacy of GABA A positive allosteric modulators (PAM) using automated patch clamp and fluorescence membrane potential assays. We determined that the use of an internal comparator (zolpidem), tested on each cell in parallel to the test compound, provides a reliable approach to measure and compare the relative efficacy of PAM ligands. Patch clamp recordings on recombinant GABA A receptors, using a multiple drug addition protocol, allows us to rank PAM ligands with different levels of efficacies. We observed that fluorescence membrane potential assays are not predictive of the relative efficacies of GABA A PAM ligands.
Introduction
Gamma amino butyric acid (Gaba) is a major neurotransmitter released in the central nervous system (CNS) and contributes to the inhibition of neuronal networks in the CNS. The GABA A receptors are complex pentameric proteins, composed of a variety of subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ), which are differentially expressed in the CNS. 1, 2 Activation of GABA A receptors by the endogenous agonist Gaba triggers an inward chloride current that hyperpolarizes the cell and contributes at the synaptic level to the generation of inhibitory postsynaptic currents. GABA A receptors have been the key focus of drug discovery efforts over the past decades, and major pharmacological tools have been developed for therapeutic use in epilepsy, depression, anxiety, and sleep disorders. [2] [3] [4] Benzodiazepines are a major drug class that act as positive allosteric modulators (PAMs) of the Gaba site by binding at the interface between the α and γ subunit of GABA A receptors. 5, 6 The chronic activation of GABA A receptors by use of agonists or PAMs leads to major tolerability issues and abuse liabilities, which often limit the clinical use of such drugs. To overcome these issues, recent strategies have focused on the development of drugs with low relative intrinsic efficacy or that selectively potentiate a specific GABA A receptor subtype to a partial level. 4 Such compounds may either act through the agonist site or bind to the allosteric site and should potentially alleviate the adverse effects mediated by the use of classical benzodiazepines. The functional characterization of such compounds can be achieved by recording GABA A currents in recombinant systems using standard patch clamp recordings. 7 However, the identification of novel GABA A modulators involves the screening of large chemical libraries and consequently the development of appropriate high-throughput screening assays. Different methods have been described that allow for the functional screening of GABA A receptors including 36 Clflux, 8 Iinflux, 9, 10 fluorescence resonance energy transfer assay, 11 FLIPR assay, 12 and automated patch clamp. 13 Although these screening methods have been successfully used to identify and to determine GABA A modulator potencies, only a few have so far studied the accurate measurement of the relative efficacy of the GABA A modulators. Analyzing the relative efficacy of GABA A PAMs requires appropriate experimental protocols in which agonist concentration, reference compound, and GABA A receptor expression are monitored. In this study, we describe the design of an experimental approach to screen for the relative efficacy of GABA A modulators using an automated patch clamp system. In addition, we investigate whether the relative efficacy could be determined by using a highthroughput fluorescence membrane potential (FMP) assay.
Materials and Methods

GABA A Cell Line
The human GABA A receptor subunits α1 (NM_000806), β2 (accession number NM_021911), and γ2S (accession number BC_059389) have been stably expressed in a CHO-K1 cell line using the Fugene 6 (Roche, Basel, Switzerland) transfection protocol.
CHO-K1 cells, stably expressing the α1/β2/γ2S subunits of the human GABA A receptor, were cultured using standard culture media Ham's F-12 with glutamine (GIBCO, Carlsbad, CA) containing 10% fetal bovine serum (FBS; Lonza, Basel, Switzerland), 1% penicillin + streptomycin (Lonza), and 400 μg/mL G418 (GIBCO) + 250 μg/mL Zeocin (Invitrogen, Carlsbad, CA). Cells were passaged using trypsin EDTA 0.05% solutions and plated at 10,000 cells/cm 2 or 5000 cells/cm 2 density in a T-75 flask (Sarstedt, Nümbrecht, Germany) 2 to 3 days before use on the automated patch clamp platform (PatchXpress 7000A; Axon Instrument, Union City, CA). The day of the experiment, cells were harvested using Accumax treatment (Sigma, St. Louis, MO) and allowed to recover for 90 min at room temperature before being used on the PatchXpress system.
Electrophysiology Recordings
GABA
A receptor chloride currents were recorded using the automated patch clamp platform PatchXpress 7000A (Axon Instrument). During all procedures, the holding potential was set to -60 mV. Whole-cell compensation was automatically set before each experiment. Current traces were recorded by patch clamp amplifier ( The potentiation of GABA A -evoked chloride currents in the presence of drug was determined and compared with the maximum potentiation in the presence of 1 μM zolpidem. The procedure for sequential application of 5 μM Gaba alone or co-applied with drugs is shown in Figure 1A . First, the vehicle DMSO 0.5% is tested followed by 2 rapid applications (45 μL/s) of 5 μM Gaba (G1, G2) for 5 s at an 80 s interval. After each application, Gaba is washed out for 30 s with extracellular solution. The cells are subsequently incubated in the presence of 1 μM zolipem for 1 min followed by one coadministration of Gaba 5 μM + zolpidem 1 μM (Z+G3) to evoke maximal chloride currents. Cells are 20 are used to verify the stability of the response followed by the coapplication in the presence of zolpidem (preincubated for 1 min). Each step is followed by a washout of the agonist and test compound (see the "Materials and Methods" section). An additional response to Gaba at EC 20 is measured to evaluate the washout of zolpidem, followed by a preincubation of the test compound (for 5 min) and eventually the coapplication with Gaba EC 20 to measure the potentiation of the compound. subsequently washed with extracellular solution to remove zolpidem followed by a new application of 5 μM Gaba (G4). The cells for which G4 responds to 80% to 120% of G2 are included into the analysis. The effects of test compounds alone are evaluated during the 5 min incubation to record baseline chloride currents followed by a coapplication of test compound and 5 μM Gaba (C+G5) to record maximal GABA A current potentiation.
The relative efficacy is calculated as the ratio of the maximal current amplitudes evoked in the presence of test compound and zolpidem [(C + G5)/(Z + G3)].
Validation criteria for each tested cell were as follows: (1) current amplitude higher than 150 pA, (2) stable leak current ≤200 pA, and (3) potentiation of Gaba response by zolpidem >180% [(Z + G3)/G2].
Half-maximal effective concentration (EC 50 ) values were determined by nonlinear regression analysis using a sigmoidal dose-response (variable slope) equation (GraphPad software version 5 for windows, San Diego, CA).
Fluorescence Measurements
GABA A receptor activation was measured using an FMP dye (Molecular Devices) as previously described. 14 Cells were seeded into 96-well clear-bottom plates the day before the experiment at a density of 35,000 cells/well. The cell culture media were removed and replaced with 180 μL of Hanks balanced salt solution (HBSS) containing Hepes 20 mM pH 7.4 and FMP dye. Test compounds were prepared in HBSS Hepes 20 mM pH 7.4 (1% DMSO), and 20 μL were added to the cell plate (in triplicate) and incubated for 30 min at room temperature. Each test plate contained the positive controls zolpidem (1 μM) and bretazenil (0.1 μM). Basal fluorescence (F 0 ) was recorded in a Flexstation reader (Molecular Devices) using an excitation and emission wavelength of 545 nm and 572 nm, respectively. Gaba (20 μL) was added with a Multidrop dispenser (Thermo Scientific, Waltham, MA) system and incubated for 6 min at room temperature before final fluorescence (F final ) measurement. The addition of Gaba to the GABA A receptor cell line induces an increase of the FMP dye fluorescence response that reaches maximal levels after 6 min. The Gaba EC 20 value was checked before each experiment using a dose range of 10 nM to 100 μM. Fluorescence data were normalized using the equation F = (F final -F 0 )/F 0 .
All data are represented as mean ± standard deviation (SD). Power analyses have been performed with SAS 9.2 Software.
Results and Discussion
Automated Patch Clamp Studies
In this study, we describe an automated patch clamp protocol to determine the relative efficacy of PAMs of the GABA A receptor in order to rank ligands with various relative efficacies and especially compounds with low potentiation levels such as bretazenil. Such compounds are often referred as "partial" PAMs (or wrongly termed partial agonists), and efficacy has been determined in the absence 15 or in the presence of a comparator, 7 which makes direct comparison quite difficult. For the screening of GABA A agonists, a maximal dose of Gaba is generally used to calculate functional efficacy, whereas for the screening of positive allosteric modulators, compounds acting on the benzodiazepine site, Gaba concentrations at EC 5 to EC 20 should be considered. Indeed, the cellular response to Gaba (e.g., Gaba at EC 20 ) is dependent on GABA A receptor expression levels and receptor combinations (different subtypes or αβ vs. αβγ containing receptors), and such heterogeneity may be expected during expression of recombinant GABA A receptors. 13 In this study, we selected zolpidem as an internal comparator because of its medium GABA A affinity and its convenient washout properties. We evaluated the activity of zolpidem on the human α1β2γ2S GABA A receptor stably expressed in a CHO cell line by using the automated patch clamp system. Figure 2A shows the potentiation of GABA A currents by 1 μM zolpidem, inducing a leftward shift of the Gaba dose-response curve. Zolpidem produced GABA A potentiation with a pEC 50 value of 7.7 ± 0.15 (n = 5). The potentiation by zolpidem (1 μM) is highest at Gaba EC 20 and decreases at higher Gaba concentrations ( Fig. 2A) , and the analysis of 1776 patched cells indicates that zolpidem potentiates Gaba EC 20 by 254% ± 68% (Fig. 2B) . The response of zolpidem was also very stable over a large number of cell passages ( Fig. 2B; passage 8-28 ), reflecting the stability of the GABA A receptor expression levels. Less than 5% of the cells showed a response inferior to 150%, most probably corresponding to cells with altered GABA A receptor pharmacology, and therefore we generally used a cutoff of 180% response (average -1 SD) of zolpidem (1 μM) to validate the cells in our screening assay.
The relative efficacy of a PAM may vary from cell to cell based on receptor combination and expression levels, and consequently, the use of an internal comparator is key to normalize the measured potentiation values. We decided to develop a novel protocol in which the efficacy of a PAM will be calculated based on the maximal response of zolpidem (1 μM) for each cell. Figure 1A shows the screening protocol that has been established to measure the relative efficacy of test compounds. First, two additions of Gaba at EC 20 are added to the cells in order to establish a stable GABA A response. This step is followed by an incubation of the positive control zolpidem (1 μM, 1 min) and the potentiation with Gaba, which provides the maximal GABA A potentiation value of the cell. After washout of the positive control, a new Gaba EC 20 is added to ensure return to control values followed by incubation of the test compound and a final potentiation with Gaba EC 20 . A preincubation step of 5 min with the test compounds should reduce the risk of underestimating the efficacy of ligands with slow binding kinetics. Coapplication is convenient when testing at rather high ligand concentrations, but it has been reported that, for example, abecarnil has slow kinetics 16 and therefore requires several minutes to produce its maximal effect.
We selected a set of GABA A reference compounds, all described to bind to the benzodiazepine site, and evaluated their relative efficacy to zolpidem (1 μM) in our PatchXpress protocol. All compounds were tested at a single dose, which produces maximal potentiation in our experiments, and their relative efficacy was calculated as described in the "Material and Methods" section. The control values in our experiments showed a ratio of 0.35 ± 0.07 (n = 12), which should not be interpreted as a potentiation effect of the vehicle but results from the contribution of the Gaba EC 20 response. Bretazenil (0.1 μM) produces the lowest potentiation with a relative efficacy of 0.46 ± 0.09 (n = 52), in agreement with its described profile as a PAM with partial efficacy. 17 All other compounds showed relative efficacies between 0.61 and 0.82 (see Table 1 ). The effects of zolpidem in these experiments were quite reproducible, as shown by the relative efficacy of 0.96 ± 0.19 (n = 14) when tested against itself. The results provide a direct comparison between GABA A PAMs and show that different levels of efficacies can be measured using this protocol. Power analyses indicated that a minimum sample size of 14 is needed to reach the level of significance (Student t test, α = 0.05; two-tailed; power 80%, SD = 0.089) when the difference of relative efficacy is equal to 0.1 between two compounds. The relative efficacies of the ligands determined in our assay are in agreement with the ranking of potentiation levels previously determined in a chloride flux assay on GABA A and in which chlordiazepoxide was used an internal comparator. 7 Chlordiazepoxide, which produces similar potentiation levels at different alpha-containing receptors, has also been described as a good internal standard when it comes to the comparison of compound efficacies between different GABA A receptor subtypes. 7 To what extent do Gaba EC 20 potentiation levels predict the relative efficacy of a PAM? To address that question, we compared the calculated relative efficacies (vs. zolpidem) with the Gaba EC 20 potentiation levels obtained from a data set of ~1100 cells that have been measured during screening activities. Figure 1B shows the relationship between the calculated efficacy levels and Gaba EC 20 potentiation values. We conclude that the two efficacy values correlate but only if the cells that show a low response to zolpidem (open circles) have been discarded. Indeed, the cells that show a response to zolpidem inferior to 180% have a general tendency to underestimate the efficacy levels when using Gaba EC 20 potentiation measurements.
FMP Approach for the Screening of GABA A PAMs
We further evaluated the use of a different technology platform that should enable the screening of GABA A PAMs with a higher throughput. The screening of voltage-and ligand-gated ion channels has been facilitated by the introduction of FMP dyes. Such dyes respond to membrane potential changes induced by the channel activation, and the resulting fluorescence changes can be easily measured with standard fluorescence readers. Activation of the GABA A receptor cell line by Gaba leads to a strong and dose-dependent increase of the FMP dye fluorescence (EC 50 ~1 μM), reaching a maximal level of 68% over baseline (data not shown). The GABA A response, when stimulated with a low dose of Gaba at EC 20 , is potentiated by a set of PAM references known to act at the benzodiazepine site (Fig. 3A) .
The pEC 50 values of the reference drugs calculated from these experiments correlate with the pIC 50 values measured from binding of the drugs to the [ 3 H]flunitrazepam site in the rat brain membranes (Fig. 3B) , confirming that the pharmacologic activity of the GABA A PAMs is reproduced in our stable cell line. Furthermore, the testing of a larger set of GABA A compounds, known to bind to the central benzodiazepine binding site, resulted in a good correlation (r 2 = 0.75) between function and binding activity. However, we were interested to determine if the FMP assay may also predict the functional efficacy of a compound when compared with patch clamp data. We tested the effects of bretazenil, described as a PAM with low efficacy on GABA A , and observed that this drug potentiated the Gaba EC 20 response to about half of the response of zolpidem (25% ± 7% vs. 52% ± 14%, n = 61). We further evaluated the fluorescence approach for screening GABA A PAMs with the aim of establishing whether the measured efficacies are comparable to the data observed in patch clamp experiments. We selected a set of ~40 compounds that have been identified by [ 3 H] flunitrazepam binding to rat brain membranes and determined their functional efficacy on GABA A receptors using the FMP assay. The relative efficacy (vs. zolpidem) was calculated based on the maximal response, and we then retested the compound at the same concentration using the PatchXpress platform. Figure 3C shows the relationship between relative efficacies, all normalized to the maximal response of zolpidem, measured by two different screening platforms. No correlation was observed between the two approaches, and some compounds were even completely inactive in the FMP assay, although they produced significant potentiation in patch clamp experiments (Fig.  3C , data points on y axis). The results indicate that the FMP assay may be suitable for screening the functional effects of GABA A PAMs acting at the benzodiazepine site but may not be a good platform to characterize and compare the efficacy of test compounds.
The protocol described in this study provides a first approach for the determination of PAM efficacy on GABA A receptors using automated patch clamp platforms. Although the study was limited to the testing of ligands acting at the benzodiazepine site, it would be interesting to further validate the approach with a larger and more diverse set of PAMs and to explore different GABA A receptor subtypes.
GABA A ligands still offer a large panel of therapeutic opportunities, and hence, the profile of agonists and PAMs in terms of binding affinity, receptor selectivity, and intrinsic efficacy needs to be carefully established. The automated patch clamp protocol that we characterized in this study should permit us to identify compounds with low, medium, or high efficacy and thus provide a rational way to select compounds with the desired profile.
